Last $5.25 USD
Change Today +0.29 / 5.85%
Volume 1.6M
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

agenus inc (AGEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/12/15 - $6.49
52 Week Low
04/15/14 - $2.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AGENUS INC (AGEN)

agenus inc (AGEN) Related Businessweek News

No Related Businessweek News Found

agenus inc (AGEN) Details

Agenus Inc., a biopharmaceutical company, is developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines, and adjuvants. Its proprietary discovery engine Retrocyte Display is designed to generate therapeutic antibody drug candidates incorporating full-length IgG format human antibody libraries expressed in mammalian B-lineage cells. The company’s portfolio of checkpoint modulator programs is advancing in preclinical development. Its heat shock protein vaccines for cancer and infectious disease are in Phase II studies. The company’s QS-21 Stimulon adjuvant platform, which is partnered with GlaxoSmithKline and Janssen, includes various candidates in Phase III trials. In addition, it has 23 programs are in clinical development. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

114 Employees
Last Reported Date: 03/7/14
Founded in 1994

agenus inc (AGEN) Top Compensated Officers

Founder, Executive Chairman and Chief Executi...
Total Annual Compensation: $489.7K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $215.7K
Chief Compliance Officer, Vice President, Gen...
Total Annual Compensation: $256.5K
Chief Business Officer
Total Annual Compensation: $183.7K
Compensation as of Fiscal Year 2013.

agenus inc (AGEN) Key Developments

Incyte Corporation and Agenus Enters into Multi-Year Global Immuno-Oncology Agreement

Incyte Corporation and Agenus have entered into a multi-year global immuno-oncology agreement that will leverage the latter's Retrocyte Display antibody discovery platform in order to develop new cancer immunotherapeutics. The licence, development, and commercialisation alliance will start by developing 'checkpoint modulator antibodies' against the following targets; glucocorticoid-induced tumour necrosis factor receptor (TNFR)-related protein (GITR); tumour necrosis factor (TNF) receptor superfamily member 4 (OX40); lymphocyte-activation gene 3 (LAG3); and hepatitis A virus cellular receptor 2 (TIM-3). It will also potentially pursue other targets in the future. The partners will split costs and profits equally for the GITR and OX40 programmes, and Agenus will be eligible for a potential USD 20 million in milestone payments for each product.

Agenus Inc. - Special Call

To discuss Agenus Inc.'s global license, development and commercialization agreement with Incyte Corporation for novel immuno-oncology antibodies

Incyte and Agenus Announce Global Alliance to Develop Novel Immuno-Oncology Antibodies

Incyte Corporation and Agenus Inc. announced a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus proprietary Retrocyte Display antibody discovery platform. The alliance will initially focus on the development of checkpoint modulator antibodies directed against GITR, OX40, LAG-3 and TIM-3. Agenus and Incyte will share all costs and profits for the GITR and OX40 antibody programs on a 50:50 basis, with Agenus eligible for potential milestones; TIM-3 and LAG-3 are royalty-bearing programs to be funded by Incyte, with Agenus eligible for potential milestones and royalties. The first clinical trials are expected to be initiated in 2016. Under the terms of the agreements between the parties, Incyte will make upfront payments to Agenus totaling $25 million and invest $35 million by purchasing approximately 7.76 million newly issued shares of Agenus common stock at a price of $4.51 per share. In addition to the initial four target programs in the alliance, the parties have an option to jointly nominate and pursue additional targets within the framework of the multi-year collaboration.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGEN:US $5.25 USD +0.29

AGEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 63.1x
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 48.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENUS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at